TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39268981
Drug: Pegaspargase, etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy (IFRT)
Study: 39269742
Drug: Self-Care Self-Efficacy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Care Self-Efficacy Index in Oral Anticoagulation Therapy Management (SCSE-OAC)
Study: 39270151
Drug: Clopidogrel-aspirin (days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin (days 1-21) followed by clopidogrel (days 22-90)
Study: 39270151
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone for 90 days
Study: 39270380
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab with chemotherapy
Study: 39270686
Drug: Once-weekly insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly insulin efsitora alfa
Study: 39270695
Drug: Savolitinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 600 mg once daily for patients with bodyweight ≥50 kg; 400 mg once daily for patients with bodyweight <50 kg, administered in 21-day cycles.
Study: 39270701
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of the intervention (specific intervention not provided in the abstract)
Study: 39270702
Drug: Atezolizumab, venetoclax,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab, venetoclax, and obinutuzumab combination
Study: 39270828
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) for oligoprogressive disease in 1 to 5 fractions while maintaining systemic therapy (ST)
Study: 39271104
Drug: Subcutaneous daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous daptomycin (10 mg/kg)
Study: 39271104
Drug: Intravenous daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous daptomycin (10 mg/kg)
Study: 39271104
Drug: Subcutaneous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous placebo (NaCl 0.9%)
Study: 39271158
Drug: Somapacitan and
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Somapacitan and Daily GH
Study: 39271928
Drug: ICVB-1042 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICVB-1042 administered intravenously or intratumorally
Study: 39271928
Drug: ICVB-1042 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICVB-1042 administered intravenously
Study: 39272058
Drug: F-627 (efbemalenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-627 (efbemalenograstim alfa) 20 mg once per cycle
Study: 39272058
Drug: Filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (5 µg/kg/d) daily
Study: 39272164
Drug: Cooperative medication
Normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooperative medication reviews conducted by MipAC physicians, supervised by geriatricians, and in collaboration with general practitioners
Study: 39272164
Drug: Cooperative medication
Normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooperative medication reviews
Study: 39272210
Drug: Transdiagnostic Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic Cognitive Remediation Therapy (TCRT)
Study: 39272232
Drug: Positive CD
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive CD serology screening for antitissue transglutaminase antibodies in individuals with predisposing HLA-DQ2/DQ8 genotypes.
Study: 39273147
Drug: Treatment-resistant CHCs
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant CHCs
Study: 39276176
Drug: MK-8353 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353 plus pembrolizumab (arm A; MK-8353 50-350 mg twice daily)
Study: 39276176
Drug: MK-8353 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353 plus pembrolizumab (arm B; MK-8353 50-600 mg once daily)
Study: 39276176
Drug: MK-8353 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353 plus pembrolizumab (arm C; MK-8353 50-300 mg once daily every other week)
Study: 39276185
Drug: Iparomlimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iparomlimab (3 mg/kg, intravenous, once every 3 weeks)
Study: 39276619
Drug: Ad26.RSV.preF/RSV preF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF/RSV preF protein vaccine (different doses of Ad26.RSV.preF with fixed dose of RSV preF protein 150 μg)
Study: 39276782
Drug: Real-time estimation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time estimation of antibody kinetics against SARS-CoV-2 variants (delta, BA.2, XBB 1.5)
Study: 39276782
Drug: Real-time dataset
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time dataset of neutralising-antibody titres
Study: 39276782
Drug: Retrospective dataset
Normalized name: octinoxate 0.25 g in 50 mL / avobenzone 0.15 g in 50 mL / octocrylene 0.4 g in 50 mL TOPICAL LOTION [retrospect day shield broad spectrum SPF 25]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective dataset of neutralising-antibody titres
Study: 39276785
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks until disease progression
Study: 39277671
Drug: Sequential multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential multiple assignment randomization trial design including three blocks: block A (experimental agent), block B (taxane-based regimen), block C (doxorubicin-cyclophosphamide)
Study: 39277739
Drug: Quadrivalent influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent influenza vaccine (15 µg/subtype/0.5 ml/dose)
Study: 39278126
Drug: Function-focused multicomponent
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Function-focused multicomponent exercise program (twice-weekly for 6 months)
Study: 39278411
Drug: Vitamin D-3
Normalized name: Vitamin D-3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-3 supplementation (3000 IU daily)
Study: 39278994
Drug: Nivolumab (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (480 mg) plus Relatlimab (480 mg) for two 4-weekly cycles
Study: 39279257
Drug: 5-mg dose
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mg dose of melatonin 1 hour before bedtime for 6 weeks
Study: 39279266
Drug: Autologous Bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Bone Marrow Aspirate Concentrate (BMAC) injection during APM
Study: 39279580
Drug: Darolutamide 600
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide 600 mg twice daily plus androgen-deprivation therapy (ADT)
Study: 39279580
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus androgen-deprivation therapy (ADT)
Study: 39279639
Drug: Cagrilintide (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide (4.5 mg, once-weekly subcutaneous injection)
Study: 39279639
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg, oral)
Study: 39279719
Drug: Lutein (L)
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lutein (L) and zeaxanthin (Z) concentrations measured by HPLC
Study: 39280785
Drug: Multiple electroacupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple electroacupuncture weekly treatment group (group M) - 12 sessions (3 sessions per week)
Study: 39280785
Drug: Single electroacupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single electroacupuncture weekly treatment group (group S) - 4 sessions (1 session per week)
Study: 39280787
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously
Study: 39281757
Drug: Integrated ML
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated ML models using lifestyle factors
Study: 39281809
Drug: European Organization
Approvals — FDA: no, EMA: no, PMDA: no
Description: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Sexual Health
Study: 39281809
Drug: European Organization
Approvals — FDA: no, EMA: no, PMDA: no
Description: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire
Study: 39281971
Drug: Subcutaneous sasanlimab
Normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sasanlimab 300 mg once every 4 weeks (300 mg-Q4W)
Study: 39281971
Drug: Subcutaneous sasanlimab
Normalized name: Sasanlimab
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sasanlimab 600 mg once every 6 weeks (600 mg-Q6W)
Study: 39282041
Drug: Prophylactic infusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusion of calcium gluconate
Study: 39282896
Drug: Chemotherapy (physician's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (physician's choice)
Study: 39282897
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Study: 39282897
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks plus placebo)
Study: 39282897
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg every 3 weeks for four doses plus placebo)
Study: 39282905
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy plus perioperative chemotherapy
Study: 39282905
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy alone (control)
Study: 39282905
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (control)
Study: 39283234
Drug: Individualized, goal-oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, goal-oriented intervention; details on dosage and duration not specified.
Study: 39283290
Drug: Itacitinib 400
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib 400 mg orally daily, 28-day cycle
Study: 39284329
Drug: Tivozanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib plus nivolumab (0.89 mg per day orally + 480 mg every 4 weeks intravenously)
Study: 39284329
Drug: Tivozanib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib monotherapy (1.34 mg per day orally)
Study: 39284329
Drug: Tivozanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib plus nivolumab (for patients with ICI as immediate previous therapy)
Study: 39284329
Drug: Tivozanib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib monotherapy (for patients with ICI as immediate previous therapy)
Study: 39284329
Drug: Tivozanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib plus nivolumab (for patients with non-ICI as immediate previous therapy)
Study: 39284329
Drug: Tivozanib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib monotherapy (for patients with non-ICI as immediate previous therapy)
Study: 39284329
Drug: Tivozanib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib monotherapy
Study: 39284337
Drug: Belzutifan 120
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan 120 mg once daily until unacceptable toxicity, disease progression, or patient decision to withdraw.
Study: 39284697
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg daily (after 1 month at 40 mg daily)
Study: 39285295
Drug: LDL-C levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C levels > 2.6 mmol/L (Groups 3 and 4)
Study: 39285295
Drug: LDL-C levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C levels ≤ 2.6 mmol/L (Groups 1 and 2)
Study: 39285313
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter balloon combined with oral estrogen therapy
Study: 39285365
Drug: Psychoeducational programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational programme supplementing Treatment As Usual (TAU)
Study: 39285418
Drug: Investigational gene
Normalized name: INVESTIGATIONAL GENE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational gene therapy (resamirigene bilparvovec)
Study: 39285437
Drug: Ketoprofen (NSAID)
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen (NSAID) 100 mg every 12 hours for 48 hours after surgery
Study: 39286575
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg sprifermin every 12 months
Study: 39286575
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg sprifermin every 6 months
Study: 39286575
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg sprifermin every 12 months
Study: 39286575
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg sprifermin every 6 months
Study: 39286636
Drug: LY01610 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY01610 at 60 mg/m²
Study: 39286636
Drug: LY01610 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY01610 at 80 mg/m²
Study: 39286890
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Therapy (Pulmonary Hypertension Drugs)
Study: 39287102
Drug: Preoperative assessment
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative assessment of U neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acid-binding protein (L-FABP)
Study: 39287102
Drug: Combined assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined assessment of U osmolality (OSM), U kidney injury molecule 1 (KIM-1), and tissue inhibitor of metalloproteinase (TIMP-1) within 48 h post-LT
Study: 39287249
Drug: sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 2 mg/kg (Group S)
Study: 39287249
Drug: sugammadex 1
Normalized name: sugammadex 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 1 mg/kg with neostigmine 20 µg/kg + atropine 10 µg/kg (Group S1N)
Study: 39287249
Drug: sugammadex 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 1.5 mg/kg with neostigmine 20 µg/kg + atropine 10 µg/kg (Group S2N)
Study: 39287249
Drug: sugammadex (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex (both doses) with neostigmine
Study: 39287566
Drug: First-line protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line protease inhibitor (PI)-based regimen
Study: 39287606
Drug: Mathematical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mathematical model predicting relapse probability based on M-protein dynamics and response histories up to 12 months of treatment.
Study: 39287821
Drug: ABBV-011 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-011 monotherapy (1.0 mg/kg every 3 weeks)
Study: 39287821
Drug: ABBV-011 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-011 monotherapy (various doses up to 2.0 mg/kg)
Study: 39287964
Drug: Onradivir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onradivir 600 mg
Study: 39287964
Drug: Onradivir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onradivir 600 mg (mild hepatic impairment)
Study: 39287964
Drug: Onradivir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onradivir 600 mg (moderate hepatic impairment)
Study: 39288373
Drug: Peer Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peer Intervention to Link Overdose survivors to Treatment (PILOT) - a 6-month, PSS-led intervention tailored to each participant's goals to reduce overdose risk behavior.
Study: 39288373
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) - standard-of-care overdose materials, education, and services provided through the participating EDs.
Study: 39288528
Drug: PIPAC-OX (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC-OX (90 mg/m2) combined with systemic nivolumab
Study: 39288781
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab (200 mg IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant pembrolizumab (200 mg IV every 3 weeks)
Study: 39288781
Drug: Neoadjuvant placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant placebo (IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant placebo (IV every 3 weeks)
Study: 39288781
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab plus chemotherapy
Study: 39288781
Drug: Neoadjuvant placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant placebo plus chemotherapy
Study: 39288844
Drug: Subcutaneous nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nivolumab (1200 mg every 4 weeks)
Study: 39288844
Drug: Intravenous nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nivolumab (3 mg/kg every 2 weeks)
Study: 39289029
Drug: E6742 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6742 100 mg
Study: 39289029
Drug: E6742 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6742 200 mg
Study: 39289057
Drug: Esomeprazole/magnesium hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole/magnesium hydroxide 40/350 mg
Study: 39289057
Drug: Enteric-coated esomeprazole
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated esomeprazole 40 mg
Study: 39289145
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg daily)
Study: 39289377
Drug: 20 mcg
Normalized name: Caverject 20 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg single dose of H10ssF vaccine
Study: 39289377
Drug: 60 mcg
Normalized name: Aranesp 60 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mcg two doses of H10ssF vaccine
Study: 39289825
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (TU)
Study: 39289825
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of testosterone therapy (TU) and progressive resistance training (Combo)
Study: 39290050
Drug: Intravenous interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous interventions (typical care)
Study: 39290050
Drug: Typical care
Normalized name: Aqua Care Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical care (intravenous metoclopramide and ketorolac)
Study: 39290129
Drug: Agent PCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent PCB
Study: 39290519
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for smoking cessation, n = 30, implemented in group-based sessions over an eight-week period
Study: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 50 mg/kg with TBI 2 Gy, ATG and fludarabine
Study: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 100 mg/kg with TBI 2 Gy, ATG and fludarabine
Study: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 0 mg/kg with TBI 2 Gy, ATG and fludarabine
Study: 39290639
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 150 mg/kg with TBI 2 Gy, ATG and fludarabine
Study: 39290680
Drug: Transcatheter edge-to-edge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter edge-to-edge repair (TEER) with the MitraClip device plus guideline-directed medical therapy (GDMT)
Study: 39290817
Drug: Mean transvalvular
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean transvalvular pressure gradient to effective orifice area ratio (MG/EOA)
Study: 39290817
Drug: MG/EOA ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG/EOA ratio
Study: 39290981
Drug: GSK3326595 400
Normalized name: Protein arginine methyltransferase 5 inhibitor gsk3326595
DrugBank: Pemrametostat (DB19170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3326595 400 mg once daily
Study: 39290981
Drug: GSK3326595 300
Normalized name: Protein arginine methyltransferase 5 inhibitor gsk3326595
DrugBank: Pemrametostat (DB19170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3326595 300 mg once daily
Study: 39291052
Drug: Anxiolytic drugs
Normalized name: ANXIOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytic drugs (alprazolam, bromazepam, lorazepam, meprobamate, midazolam, oxazepam)